1.
Transplant Proc
; 37(5): 2179-80, 2005 Jun.
Article
in English
| MEDLINE
| ID: mdl-15964372
ABSTRACT
Current rescue therapies for acute steroid-resistant rejection, such as OKT3 and high-dose tacrolimus, are not uncommonly associated with side effects that contribute to significant morbidity of the patient. Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 receptor antagonist on the surface of activated T lymphocytes. It has until now only been used as immunoprophylaxis in adult liver transplant patients. In this report, we describe the use of Basiliximab as rescue therapy in a case of acute steroid-resistant rejection in an adult living related liver transplant recipient.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Graft Rejection/drug therapy , Immunosuppressive Agents/therapeutic use , Liver Transplantation/immunology , Recombinant Fusion Proteins/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Basiliximab , Female , Humans , Liver Function Tests , Middle Aged , Postoperative Period
2.
Transplant Proc
; 32(7): 2139, 2000 Nov.
Article
in English
| MEDLINE
| ID: mdl-11120104
Subject(s)
Liver Transplantation/statistics & numerical data , Adult , Cadaver , Child , Hepatitis B/complications , Humans , Liver Cirrhosis/surgery , Liver Cirrhosis/virology , Liver Transplantation/mortality , Liver Transplantation/physiology , Living Donors , Retrospective Studies , Singapore , Survival Rate , Time Factors , Tissue Donors
3.
Transplant Proc
; 32(7): 2173, 2000 Nov.
Article
in English
| MEDLINE
| ID: mdl-11120119